The short version: GHK-Cu is a copper-binding tripeptide that occurs naturally in human plasma and is studied for its role in collagen synthesis, antioxidant gene regulation, and tissue remodeling. It is sold as a research-use-only laboratory chemical, not a medication, and injectable GHK-Cu was placed in FDA Category 2 for compounding in 2023. Before ordering, verify the supplier’s lot-specific certificate of analysis, confirm the testing laboratory is independent, and check that the listing maintains a strict research-use-only boundary. Stack Research publishes lot-specific documentation for its GHK-Cu research peptide, which is the baseline standard any researcher should expect.
Search for “buy GHK-Cu” and you will find a market with price points that range from around $30 for a 50 mg vial on some research sites to over $100 for higher-purity configurations. The spread is not explained by the cost of the raw material alone. It is explained by differences in sourcing, testing, documentation, and the degree to which each seller is willing to be transparent about what is actually in the vial.
This guide is written for laboratory researchers who need to evaluate a GHK-Cu supplier before placing an order. It covers what the published literature says about the compound, how the FDA’s regulatory posture toward injectable GHK-Cu has evolved, how to read a certificate of analysis without getting misled, and the specific questions that separate a transparent supplier from one that is hoping you will not ask.
What GHK-Cu is, and what the research shows
GHK-Cu is a tripeptide composed of glycine, histidine, and lysine, bound to a copper(II) ion. The sequence is glycyl-L-histidyl-L-lysine. It is a naturally occurring plasma molecule that was first isolated from human albumin in 1973. A review published in the International Journal of Molecular Sciences in 2018 describes GHK-Cu as a small copper-binding peptide that declines significantly with age, from approximately 200 nanograms per milliliter in young adults to about 80 nanograms per milliliter by age 60. The authors review gene data showing that GHK-Cu modulates the expression of a wide range of genes involved in tissue remodeling, inflammation, and oxidative stress response.
The mechanistic literature is extensive. A review published in BioMed Research International in 2015 describes GHK-Cu as a natural modulator of multiple cellular pathways in skin regeneration. The authors report that GHK-Cu stimulates collagen synthesis, promotes angiogenesis, and regulates the expression of matrix metalloproteinases and their inhibitors. The paper notes that the compound is active at very low concentrations, with biological effects observed in the nanomolar range.
A separate review published in BioMed Research International in 2014 examined the interaction of GHK with DNA and its potential role in resetting gene expression patterns associated with aging. The authors describe GHK as a molecule that can reverse the expression of approximately 4,000 genes to a more youthful pattern, including genes involved in collagen production, antioxidant defense, and inflammatory signaling. The review emphasizes that these findings are based on gene expression data and that clinical outcome data is limited.
What the research does not establish is a safe and effective dose for any human use outside of a clinical trial setting. The clinical literature describes GHK-Cu primarily in topical formulations, with a limited number of small human studies. A 2026 review published in Pharmaceutics assessed the translational evidence for GHK-Cu and concluded that the highest biological evidence level for photoaging and cosmetic remodeling is B2 to B5, corresponding to small pilot studies and conference-level reports. The authors note that injectable GHK-Cu lacks published human trials, and that the strongest near-term clinical target is topical application for postprocedural repair and acute wound healing.
A Phase 2 randomized, double-blind, vehicle-controlled split-wound study of topical GHK-Cu gel for acute skin wound healing was recruiting as of August 2026. The study is designed to evaluate whether a topical gel containing GHK-Cu can safely accelerate re-epithelialization of standardized acute skin wounds in healthy adults compared with a matching vehicle gel. No efficacy results were available at the time of writing.
How GHK-Cu compares to BPC-157 and TB-500 in research
GHK-Cu is often discussed alongside BPC-157 and TB-500 because all three are studied for tissue repair applications. The three compounds, however, operate through different mechanisms and have different evidence profiles.
BPC-157 is a synthetic pentadecapeptide derived from gastric juice protein. It is studied primarily for angiogenic and anti-inflammatory properties in preclinical models. TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in cell migration and actin regulation. A physician-authored review of peptide stacks describes the three compounds as addressing different phases of wound healing: BPC-157 drives angiogenesis, TB-500 promotes cell migration, and GHK-Cu supports matrix remodeling. The review notes that GHK-Cu has the strongest human clinical evidence for topical skin use, with multiple published randomized controlled trials, while BPC-157 and TB-500 rely mostly on preclinical data and lack controlled human trials for skin indications.
The evidence gap matters for researchers. A compound that has been studied in human clinical trials, even small ones, has a different data profile than a compound studied only in animal models. GHK-Cu’s topical evidence base is more developed than its injectable evidence base, and the published literature reflects that distinction. Researchers should be precise about which route of administration a given study used when interpreting results.
Video: What the research says about GHK-Cu
This third-party video provides general context on GHK-Cu research. It is not affiliated with Stack Research and is not a substitute for laboratory documentation or the published literature.
The regulatory status of GHK-Cu
GHK-Cu is not an FDA-approved drug. It has not received authorization from the FDA, the European Medicines Agency, or any other national regulatory body for human use. The compound is sold as a research-use-only laboratory chemical, and the Stack Research GHK-Cu product page states that the product is supplied only for lawful in-vitro laboratory or analytical research and that the page provides no dosing, administration, treatment, or diagnostic guidance.
The regulatory history of injectable GHK-Cu is more complicated than many listings acknowledge. In September 2023, the FDA placed 19 experimental peptides, including injectable GHK-Cu, into Category 2 of the interim 503A bulk drug substances list. A 2026 review in the Georgian Medical News explains that Category 2 designation signifies that the FDA considers a substance to raise significant safety concerns and does not permit compounders to use it in preparing drug products while evaluation continues. The designation was based on concerns including insufficient human clinical trial evidence, variability in chemical composition across production batches, potential immunogenicity, and absence of adequate pharmacovigilance data.
In April 2026, the FDA removed 12 peptides from Category 2 and scheduled a Pharmacy Compounding Advisory Committee review. Legal analysis from Orrick notes that GHK-Cu was removed from Category 1 for non-injectable routes of administration, and injectable GHK-Cu was removed from Category 2, after the nominations were withdrawn by the nominators. The removal from Category 2 does not constitute authorization for compounding. It moves the substance into a regulatory grey zone pending formal PCAC evaluation, which was scheduled for before the end of February 2027.
For researchers, the practical implication is that the regulatory environment around injectable GHK-Cu is unsettled. A supplier that claims the compound is legal to sell for human use is misrepresenting the current regulatory posture. A supplier that sells it as a research-use-only chemical and provides analytical documentation is operating within a recognized research supply channel.
The researcher’s sourcing checklist for GHK-Cu
The difference between a defensible purchase and a gamble comes down to documentation. Here is what to check, in order.
1. Lot-specific certificate of analysis, not a generic sample
A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. A supplier that shows a single COA for “GHK-Cu” without tying it to a lot number is showing you marketing material, not a laboratory report. The COA should list the lot number, the testing laboratory, the report ID, the date the sample was received, and the date the results were published.
Stack Research publishes a lot-specific report for its GHK-Cu 50 mg research peptide. The current lot documentation shows HPLC purity of 99.47 percent, copper content of 12.85 percent, and passing results for identity by mass spectrometry. The report identifies the testing laboratory and includes a report ID that can be cross-referenced. The product page shows the exact SKU, lot number, laboratory, report ID, and sample dates alongside the price.
2. What the COA actually tests
A certificate that lists only “purity: 99%” is incomplete for a metallopeptide like GHK-Cu. The useful fields are identity by mass spectrometry, purity by HPLC, copper content, measured content, endotoxin, and sterility. Identity confirms the peptide sequence matches the reference standard. Purity by HPLC shows the percentage of the sample that is the target compound. Copper content is particularly important for GHK-Cu because the copper ion is part of the active complex. A sample that is 99 percent pure peptide but has a low copper content may not be the copper-bound form researchers expect.
A representative certificate of analysis for GHK-Cu from a chemical supplier shows the structure a complete report should follow: product name, CAS number, lot number, molecular formula, molecular weight, appearance, identity by mass spectrometry, purity by HPLC, copper content, acetic acid content, TFA ion, water content, pH, and solubility. That level of detail is the standard for a metallopeptide, not a bonus feature.
3. The research-use-only boundary
Every legitimate research peptide supplier uses the research-use-only (RUO) designation. The RUO label means the product is not intended for diagnostic, therapeutic, or human use. It is a legal boundary, not a suggestion.
What to watch for is a supplier that uses the RUO label while simultaneously publishing dosing information, before-and-after photos, or customer testimonials about human use. That combination is what the FDA has cited in warning letters. A supplier that maintains the boundary consistently is easier to trust because it is not trying to have it both ways.
4. Pricing and configuration transparency
GHK-Cu vials are typically sold in 50 mg and 100 mg configurations. The price per milligram should be calculable from the listing. If the listing obscures the vial size, bundles it with accessories, or requires a minimum order to see pricing, that is friction that makes comparison harder. Stack Research lists its 50 mg GHK-Cu vial at $79.90 with volume pricing available to verified research accounts. The product page shows the exact SKU and lot information alongside the price, which makes the listing auditable.
5. Stability and storage considerations
GHK-Cu has specific stability requirements that researchers should understand before ordering. Technical documentation on GHK-Cu stability states that the lyophilized powder should be stored at −20°C or below for long-term stability, where it can remain stable for up to three years. Reconstituted solutions should be stored at 2 to 8°C and used within a defined window. The compound is most stable in a neutral to slightly acidic pH range, ideally between 5.5 and 6.5. Extreme pH values can lead to hydrolysis of the peptide bonds or dissociation of the copper ion.
A supplier that provides storage guidance on its product page or research library is offering information that affects the integrity of the material after it ships. Stack Research’s peptide storage guide covers the handling and storage conditions that apply to lyophilized research peptides, including temperature ranges and reconstitution considerations.
How Stack Research approaches GHK-Cu documentation
Stack Research is a research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s testing page describes the analytical methods used and the laboratories that perform the work. For researchers who need to verify a supplier before ordering, the relevant questions are whether the documentation is specific to the lot, whether the testing laboratory is named, and whether the results can be independently reviewed.
The GHK-Cu product page shows the current lot report directly on the page, with the purity, copper content, and identity results visible without requiring a separate download. The COA library collects the reports for all products so that researchers can compare documentation across configurations. The company maintains a research-use-only boundary throughout its product descriptions and does not publish dosing or administration guidance.
That last point is worth emphasizing because it is the dividing line the FDA has drawn in its enforcement actions. A supplier can sell research peptides and publish analytical documentation without crossing into human-use marketing. When a supplier stays on the research side of that line, the documentation becomes the primary basis for evaluating the product. When a supplier crosses the line, the documentation is no longer the main thing being sold.
Comparing GHK-Cu documentation standards
The table below outlines the documentation elements that separate a transparent listing from an incomplete one. It is not a ranking of suppliers but a framework for evaluating any listing you encounter.
| Documentation element | What a complete listing shows | Red flag if missing |
|---|---|---|
| Lot-specific COA | Report tied to the exact lot number, with testing lab named | Generic COA or no lot number |
| Identity test | Mass spectrometry confirms peptide sequence | Purity percentage only, no identity result |
| Copper content | Reported value within specified range | Omitted entirely |
| Measured content | Actual peptide mass in the vial, not just label claim | No fill or content verification |
| Endotoxin and sterility | Pass/fail results for both | Omitted entirely |
| Research-use-only boundary | No dosing, administration, or human-use content | Testimonials, before/after photos, influencer dosing content |
| Storage guidance | Temperature and handling instructions published | No storage information on product page |
| Independent laboratory | Third-party lab named, report ID verifiable | In-house testing only, no independent verification |
The table is not a guarantee. A supplier can produce all of these documents and still be selling a product that does not match the report, which is why independent testing services exist. But a supplier that cannot produce the documents at all is not worth the time it takes to evaluate further.
Common questions researchers ask before buying GHK-Cu
Is GHK-Cu legal to buy for research purposes?
GHK-Cu is not an approved drug, so it cannot be legally sold as a medicine. Research peptides labeled for laboratory use occupy a different regulatory space. Injectable GHK-Cu was placed in FDA Category 2 in 2023 and removed from Category 2 in April 2026, pending PCAC evaluation. Researchers should purchase only from suppliers that maintain the research-use boundary and provide analytical documentation.
What purity should a GHK-Cu COA show?
Purity by HPLC above 95 percent is the typical threshold for research-grade peptides. Many suppliers report 98 to 99 percent or higher. For GHK-Cu, the purity figure is only meaningful alongside identity, copper content, and measured content results. A vial can be 99 percent pure and still contain less copper than the label claims if the complex is not fully formed.
How do I verify that a COA is real?
Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity. If a supplier cannot tell you which laboratory performed the test, the COA cannot be independently verified.
What is the difference between GHK-Cu and copper tripeptide-1?
They are the same compound. Copper tripeptide-1 is a cosmetic ingredient name for the GHK-Cu complex. Researchers should confirm the identity of any product by its COA, not by the brand name or cosmetic designation on the vial.
How should GHK-Cu be stored?
Lyophilized GHK-Cu powder should be stored at −20°C or below for long-term stability. Reconstituted solutions should be refrigerated at 2 to 8°C and used within the window specified by the supplier. The compound is most stable in a neutral to slightly acidic pH range, ideally between 5.5 and 6.5. The peptide storage guide covers handling and storage conditions for research peptides.
What should I do if a supplier’s listing makes health claims?
Treat it as a disqualifying signal. Health claims on a research peptide listing are the exact pattern the FDA has cited in warning letters. A supplier that describes what the peptide “does” for the body is marketing an unapproved drug, regardless of the research-use label elsewhere on the page.
Can I compare GHK-Cu documentation across suppliers?
Yes, and you should. The relevant fields are comparable across suppliers: purity, identity, copper content, measured content, endotoxin, sterility, and lot traceability. The guide to reading a certificate of analysis walks through each field and explains what a complete report should contain.
Important notice: This article is provided for educational and informational purposes only. It does not constitute medical, legal, or regulatory advice. Research peptides discussed here are sold exclusively for laboratory research use and are not approved by the FDA or any other regulatory agency for human or veterinary use. Nothing in this article should be construed as guidance for human consumption, dosing, or administration. Statements regarding dietary supplements and research compounds have not been evaluated by the FDA. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction. Always consult the product label, the certificate of analysis, and a qualified professional before making decisions about any substance.